Cargando…

Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer’s Disease or Dementia with Lewy Bodies

Kynurenic acid (KYNA) is implicated in cognitive functions. Altered concentrations of the compound are found in serum and cerebrospinal fluid (CSF) of patients with Alzheimer’s disease (AD). Further studies to determine whether KYNA serves as a biomarker for cognitive decline and dementia progressio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wennström, Malin, Nielsen, Henrietta M, Orhan, Funda, Londos, Elisabet, Minthon, Lennart, Erhardt, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011721/ https://www.ncbi.nlm.nih.gov/pubmed/24855376 http://dx.doi.org/10.4137/IJTR.S13958

Ejemplares similares

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2015)

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
por: Wennström, Malin, et al.
Publicado: (2015)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

The Impact of Autonomic Dysfunction on Survival in Patients with Dementia with Lewy Bodies and Parkinson's Disease with Dementia
por: Stubendorff, Kajsa, et al.
Publicado: (2012)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
por: Stubendorff, Kajsa, et al.
Publicado: (2014)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Involvement of Matrix Metalloproteinase-9 in Amyloid-β 1–42–Induced Shedding of the Pericyte Proteoglycan NG2
por: Schultz, Nina, et al.
Publicado: (2014)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
por: Mukaetova-Ladinska, Elizabeta B., et al.
Publicado: (2010)

Relative survival in patients with dementia with Lewy bodies and Parkinson’s disease dementia
por: Larsson, Victoria, et al.
Publicado: (2018)

Short-Term Response to Cholinesterase Inhibitors in Alzheimer’s Disease Delays Time to Nursing Home Placement
por: Wattmo, Carina, et al.
Publicado: (2018)

Solitary living in Alzheimer’s disease over 3 years: association between cognitive and functional impairment and community-based services
por: Wattmo, Carina, et al.
Publicado: (2014)

Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid
por: Johansson, Viktoria, et al.
Publicado: (2019)

Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies
por: Foska, Aikaterini, et al.
Publicado: (2022)

Exploring the prevalence of undetected bradyarrhythmia in dementia with Lewy bodies
por: Heyman, Isak, et al.
Publicado: (2023)

Cerebrospinal Fluid EV Concentration and Size Are Altered in Alzheimer’s Disease and Dementia with Lewy Bodies
por: Longobardi, Antonio, et al.
Publicado: (2022)

Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer’s disease: a prospective, observational study of factors affecting survival time from admission to death
por: Wattmo, Carina, et al.
Publicado: (2016)

Predictors of long-term cognitive outcome in Alzheimer's disease
por: Wattmo, Carina, et al.
Publicado: (2011)

Effects of carbonated liquid on swallowing dysfunction in dementia with Lewy bodies and Parkinson’s disease dementia
por: Larsson, Victoria, et al.
Publicado: (2017)

Reliability, validity and clinical correlates of the Quality of Life in Alzheimer’s disease (QoL-AD) scale in medical inpatients
por: Torisson, Gustav, et al.
Publicado: (2016)

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

A longitudinal study of risk factors for community-based home help services in Alzheimer’s disease: the influence of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2013)

Living with dementia with Lewy bodies: an interpretative phenomenological analysis
por: Larsson, Victoria, et al.
Publicado: (2019)

(18)F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
por: Smith, Ruben, et al.
Publicado: (2018)

NG2 cells, a new trail for Alzheimer’s disease mechanisms?
por: Nielsen, Henrietta M, et al.
Publicado: (2013)

Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis
por: Janssens, Jana, et al.
Publicado: (2018)

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies
por: van de Beek, M., et al.
Publicado: (2020)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2010)

A Longitudinal Study of Physical Function in Patients with Early-Onset Dementia
por: Tangen, Gro Gujord, et al.
Publicado: (2012)

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
por: Henjum, Kristi, et al.
Publicado: (2016)

Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer’s Disease in Clinical Practice
por: Lilamand, Matthieu, et al.
Publicado: (2022)

Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia
por: Maetzler, Walter, et al.
Publicado: (2012)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Pacemaker Implants and Their Influence on the Daily Life of Patients with Dementia with Lewy Bodies: A Qualitative Case Study
por: Heyman, Isak, et al.
Publicado: (2023)

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy
por: Wennström, Malin, et al.
Publicado: (2013)

Practical Treatment of Lewy Body Disease in the Clinic: Patient and Physician Perspectives
por: Londos, Elisabet
Publicado: (2017)

Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden
por: Zahirovic, Iris, et al.
Publicado: (2018)

Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies
por: Perra, Daniela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2kn250q8ev98nmo8it6vc8iet6